Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of belzupacap sarotalocan versus sham control for primary indeterminate lesions or small choroidal melanoma
2023-504655-27-00Phase 3Authorised
- Sponsor
- Aura Biosciences, Inc.
- Start
- Dec 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of belzupacap sarotalocan in choroidal melanoma (2 arms), sponsored by Aura Biosciences, Inc. Primary endpoint: Time to reach tumor progression. Planned start Dec 2024; status: authorised.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanoma
Beyond the preview
Go deeper on 2023-504655-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504655-27-00.